Founder's Story – Ep. 316: The French Industrialist Betting on Robotics to Cure Disease (And the Ethical Line He Won’t Cross)

Guest: Hervé de Malliard, President of Maison MGA
Host: Dan (IBH Media)
Date: February 27, 2026

Episode Overview

This episode features Hervé de Malliard, a French engineer and president of Maison MGA, a pioneering firm at the intersection of robotics, engineering, and biotechnology (“tech bio”). The conversation explores Hervé’s formative manufacturing experiences in China, the bold vision behind Maison MGA, the transformative role of robotics in healthcare, and the moral boundaries that come with world-changing technological advancements.

Key Discussion Points & Insights

1. Lessons from China's Industrial Ascent

Timestamps: 00:25–05:45

• Early Career in 1990s China: Hervé recounts working in China in the mid-90s as part of a French industrial group (Dietrich), supplying chemical reactors for pharmaceuticals.
• Observation of Rapid Progress:
  • “The speed was of the essence everywhere. Once they decide to go, then they make it happen. And very quickly, much far quickly than what we could do in the West at that time.” (Hervé, 02:48)
  • Even in the 90s, Chinese industry had a clear long-term vision, focused on sovereignty, innovation, and rapid execution.
• Long-Term Planning:
  • Hervé notes that China’s present-day industrial dominance—particularly in automotive and electric vehicles (BYD)—was already part of their plan thirty years ago.
• Key Takeaway for Entrepreneurs:
  • “Lessons learned for me was: industry is having a right perspective, know where you want to go and then execute a plan…very patient in execution, but very fast on a day-to-day basis.” (Hervé, 05:18)

2. From Global Engineering to Founding Maison MGA

Timestamps: 06:39–10:14

• Transition (1999–2010): After leaving China, Hervé managed complex engineering projects globally, including turnkey “greenfield” pharmaceutical factories.
• Focus on Clean Environments:
  • Inspired by the lack of robotics in pharmaceutical manufacturing, Hervé decided to channel Maison MGA’s expertise into integrating robotics and digital technologies for “cleanrooms”—sterile environments required for sensitive life sciences manufacturing.
• Driving Vision:
  • “So putting robots, tailor-made machines, instruments in order to address those complex engineering and put more and more robotics...to serve mainly the life science industry.” (Hervé, 09:45)

3. Defining “Tech Bio” and Its Impact

Timestamps: 10:44–14:39

• Biotech vs. Tech Bio:
  • Biotech focuses on growing biological matter and scaling large bioreactors—key to traditional pharmaceuticals and vaccines.
  • Tech bio, by contrast…
    • “is putting all the engineering capability, the complex engineering capability to personalized medicine.” (Hervé, 12:45)
    • Emphasis is on using robotics, software, and integrated systems to enable therapies tailored for one patient at a time (e.g., gene and cell therapies).
  • The convergence of hardware, software, digital diagnostics, and continuous patient feedback (via smartphones and AI) is central to tech bio’s promise.

4. The Promise and Peril of Robotics & AI in Healthcare

Timestamps: 14:39–18:08

• Excitement:
  • Hervé envisions a future (by 2050) where “almost all the known diseases of today will have treatment.”
  • “You can imagine that you can basically replace your heart...replace your liver, you can replace your muscles...possibly some people could, with a lot of money, maybe live 500 years or 1,000 years. So this is of course not very acceptable ethically.” (Hervé, 15:52)
• Ethical Line:
  • Acknowledges risk that “technology could compromise life or morality”—there must be broadly agreed ethical boundaries.
  • “I see robots as a tool, like a pen very nicely drawing or writing a book. You can also use it very badly. And it's the same for AI, is the same for robotics, it's the same for tech bio.” (Hervé, 17:32)
• Ultimate Dream:
  • Save lives that should be saved: “You will no longer have those 5 years old children that die of cancer...if we manage to save lives that have to be saved, this is of course an ultimate dream. And this is what I'm working from.” (Hervé, 16:37)

5. Notable Projects & Innovations at Maison MGA

Timestamps: 19:05–22:02

• Liquid Biopsy Instrument:
  • Developed with Stila Technologies (now Bio Rad), this instrument turns a tiny liquid sample into “20,000 nano droplets, and each of these nanodroplets individually become a PCR reactor.” (Hervé, 19:24)
  • Yields highly precise diagnosis and real-time monitoring of treatments, especially in oncology.
• Advances in Cell Therapy:
  • Collaboration with Vertex and TreeFrog Therapeutics to create 3D-encapsulated cell divisions (“like in an egg”)—seen as a game changer for cell-based therapies.
• Broader Vision:
  • “It’s clear that we are going to completely change...it’s a real game changer in biotherapies.” (Hervé, 21:46)

6. The Optimism of Progress

Timestamps: 22:18–24:16

• Mindset:
  • “I am very optimistic and I prefer to, to be optimistic and, and being wrong rather than pessimistic and being right.” (Hervé, 22:18)
  • Progress can and should be harnessed to improve the lives of people in both rich and poor countries, leveling the playing field and uplifting standards of living through innovation.
• Host’s Closing Reflection:
  • “Hopefully this is going to spread everywhere...thank you so much...I’m excited for the future.”

Memorable Quotes

• On Chinese industrial strategy:
  • “Once they decide to go, then they make it happen. And very quickly, much, far quickly than what we could do in the west.” – Hervé (02:48)
• On the intent of tech bio:
  • “All this engineering capability, whether hardware, software, driven to one patient and looping with the patient—that is tech bio.” – Hervé (13:35)
• On ethical boundaries:
  • “We need to make sure all these new technology respect life, respect humanity. And that’s the...border that has to be defined.” – Hervé (16:24)
• On optimism:
  • “I prefer to be optimistic and be wrong, rather than pessimistic and be right.” – Hervé (22:18)

Additional Highlights & Timestamps

• [03:01] – The importance of executing long-term plans with day-to-day speed.
• [09:45–10:14] – The leap from robotics in auto manufacturing to its necessity in healthcare.
• [14:39–16:00] – Anticipating societal challenges as lifespans and capabilities evolve.

Summary

This episode with Hervé de Malliard explores the thrilling—and sometimes daunting—future at the intersection of robotics, AI, and biotechnology. Hervé’s experiences illustrate the transformative impact of deliberate strategy, unrelenting execution, and innovative engineering in propelling not just companies or countries—but humanity itself—into the next era of health and progress. All this, he stresses, must be balanced with a deep ethical commitment: that technology serves humanity without overriding its moral compass. The optimism underlying his vision is both cautionary and inspiring—a hope that the world can use its ingenuity to uplift all, heal more, and draw a line against excess.